Skip to main content
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. — Investor Relations & Filings

Ticker · LENZ ISIN · US38870X1046 US Manufacturing
Open in API
Filings indexed 329 across all filing types
Latest filing 2026-04-28 Annual Report
Country US United States of America
Listing US LENZ

About LENZ Therapeutics, Inc.

https://lenz-tx.com/

LENZ Therapeutics, Inc. is a late-stage pharmaceutical company focused on developing and commercializing ophthalmic therapies to improve vision. Its primary product is VIZZ™ (aceclidine ophthalmic solution) 1.44%, an FDA-approved eye drop for the treatment of presbyopia, the age-related loss of near vision. VIZZ is the first aceclidine-based therapy for this condition, which affects an estimated 1.8 billion people globally. The product is designed to restore near vision, providing a pharmaceutical alternative to reading glasses for a broad patient population.

Recent filings

Filing Released Lang Actions
ARS - LENZ Therapeutics, Inc. (0001815776) (Filer)
Annual Report
2026-04-28 English
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
Director's Dealing
2026-03-30 English
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
Director's Dealing
2026-03-30 English
4 - LENZ Therapeutics, Inc. (0001815776) (Issuer)
Director's Dealing
2026-03-30 English
8-K - LENZ Therapeutics, Inc. (0001815776) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 24, 2026, reporting the issuance of a press release announcing financial results for the fiscal year ended December 31, 2025. The text explicitly states that the press release is attached as Exhibit 99.1 and incorporated by reference, and that the information is not "filed" for purposes of Section 18 of the Exchange Act. The document itself does not contain the financial results or detailed financial statements but rather announces the release of such information. The document length is 3688 characters, which is relatively short and consistent with an announcement rather than a full report. According to the "Menu vs Meal" rule, this is an announcement of a report (press release of financial results), not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not contain substantive financial data or the full earnings release text.
2026-03-24 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.